Tacrolimus (all routes)

Table   Graphic     exposition period:

Congenital malformations
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROB
All congenital malformations (majors, minors, majors and minors, or unspecified)0.46 [0.07, 3.05]0%2 studies430not evaluable ROB
Major congenital malformations0.37 [0.04, 3.14]-1 study421not evaluable ROB

Growth parameters and prematurity
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROB
Preterm (< 37 weeks)0.99 [0.36, 2.69]39%4 studies5082not evaluable ROB
Low birth weight (< 2500g)2.02 [0.86, 4.75]0%2 studies2743not evaluable ROB
Small for gestational age (weight)0.87 [0.12, 6.18]0%2 studies1213not evaluable ROB

Maternal consequences
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROB
Preeclampsia2.26 [0.63, 8.11]0%4 studies1949not evaluable ROB
Caesarean1.34 [0.73, 2.48]0%3 studies9270not evaluable ROB
Gestational diabete1.31 [0.05, 35.47]-1 study121not evaluable ROB
Maternal consequences (as a whole)1.18 [0.36, 3.87]-1 study3416not evaluable ROB

Neonatal disorders
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROB
Fetal distress0.48 [0.04, 5.18]-1 study15not evaluable ROB

Intrauterine deaths
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROB
Early intrauterine death (< 22 weeks)7.95 [0.37, 171.28]-1 study233not evaluable ROB
Late intrauterine deaths (> 22 weeks)0.95 [0.04, 20.57]46%2 studies342not evaluable ROB

Hide endpoints reported in only one study ...